Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) had its target price reduced by BMO Capital Markets from $491.00 to $479.00 in a report published on Thursday morning. BMO Capital Markets currently has a market perform rating on the biopharmaceutical company’s stock.
REGN has been the subject of a number of other research reports. Morgan Stanley reiterated an equal weight rating and set a $450.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 23rd. Canaccord Genuity reiterated a buy rating on shares of Regeneron Pharmaceuticals in a research report on Monday, October 16th. Barclays PLC downgraded Regeneron Pharmaceuticals from an equal weight rating to an underweight rating and dropped their price target for the company from $450.00 to $395.00 in a research report on Friday, October 20th. Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 27th. Finally, Leerink Swann reiterated an outperform rating and set a $580.00 price target (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of Hold and an average price target of $481.49.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) traded down $1.67 on Thursday, hitting $404.54. The stock had a trading volume of 771,100 shares, compared to its average volume of 886,192. The company has a market cap of $43,346.87, a P/E ratio of 35.03, a PEG ratio of 1.39 and a beta of 1.56. The company has a current ratio of 3.63, a quick ratio of 3.21 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals has a 12-month low of $340.09 and a 12-month high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same quarter last year, the company posted $3.13 EPS. equities research analysts expect that Regeneron Pharmaceuticals will post 13.77 EPS for the current year.
WARNING: This story was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.chaffeybreeze.com/2017/11/12/regeneron-pharmaceuticals-inc-regn-pt-lowered-to-479-00-at-bmo-capital-markets.html.
In other news, major shareholder Sanofi purchased 166,415 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were bought at an average cost of $480.93 per share, for a total transaction of $80,033,965.95. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the sale, the chief financial officer now owns 10,099 shares in the company, valued at $5,060,204.94. The disclosure for this sale can be found here. Insiders have sold 88,942 shares of company stock worth $42,064,076 over the last 90 days. 10.80% of the stock is currently owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. Fieldpoint Private Securities LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter worth $130,000. Sterling Investment Advisors Ltd. boosted its holdings in Regeneron Pharmaceuticals by 11.2% in the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 28 shares in the last quarter. FNY Partners Fund LP boosted its holdings in Regeneron Pharmaceuticals by 200.0% in the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 200 shares in the last quarter. Alpha Windward LLC boosted its holdings in Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 1 shares in the last quarter. Finally, IFP Advisors Inc boosted its holdings in Regeneron Pharmaceuticals by 33.2% in the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 96 shares in the last quarter. 67.63% of the stock is currently owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.